Background-The clinical benefits of statins are attributed to changes in plaque composition that lead to reduced metalloproteinase (MMP) activity and plaque stabilization. However, the molecular mechanism of this effect is unclear.
I nflammatory processes play a pivotal role in the pathogenesis of atherosclerosis, particularly in the progression of atherosclerotic plaque toward instability. 1 Rupture-prone lesions contain a large lipid core underlying a thin and collagen-poor fibrous cap, and they usually have prominent inflammatory infiltrates of macrophages and lymphocytes. 1 Macrophages produce proteolytic enzymes capable of degrading plaque constituents, including members of the metalloproteinase (MMP) family. In particular, expression of MMP-2 and MMP-9 has been shown within human atherosclerotic lesions and critically implicated in plaque rupture. 2 Production of these MMPs by macrophages occurs through a prostaglandin (PG) E 2 -dependent pathway. 2 Signaling through this pathway involves the modulation of cyclooxygenase (COX) and PGE synthase (PGES). Two isoforms of COX (COX-1 and COX-2) and PGES (cPGES and mPGES) have been identified. COX-1 and cPGES are constitutively expressed. In contrast, COX-2 and mPGES are induced in response to several stimuli in inflammatory diseases. Consistent with the hypothesis of COX-2/mPGES contributing to the clinical instability of atherosclerosis, we have recently reported the overexpression of COX-2/mPGES as a pathway underlying the enhanced release of active MMPs in symptomatic atherosclerotic plaques.
Hypercholesterolemia is a major risk factor for atherosclerosis, and recent clinical trials have shown that statins reduce cardiovascular events and mortality in humans. 3 Clinical benefits of statins are greater than those expected on the basis of the modest change in arterial stenosis severity. These data suggest that statins may somehow stabilize plaques against disruption.
In this regard, it is of extreme interest to analyze the ability of statins to reduce gelatinolytic activity. Crisby et al 4 recently demonstrated that statins may decrease inflammation and MMP-2 and increase collagen content in human carotid plaques. However, the specific molecular mechanisms by which statins may influence MMP generation in plaque macrophages are still unknown.
The possibility that the suppression of COX-2 and mPGES by statins might represent a mechanism of plaque stabilization led us to investigate whether it would modulate MMP production by macrophages into atherosclerotic plaques. Here, we report reduced MMP production by macrophages in carotid plaques of patients randomized to simvastatin, most likely because of a reduction in PGE 2 synthesis as a result of the suppression of COX-2/mPGES.
Methods

Patients
We studied 70 of 128 consecutive surgical inpatients who had been enlisted to undergo carotid endarterectomy for extracranial highgrade (Ն70%) internal carotid artery stenosis. All patients were symptomatic according to North American Symptomatic Carotid Endarterectomy Trial classification 5 and had LDL cholesterol (LDL-C) ranging between 100 and 129 mg/dL. Patients were randomized to 4-month treatment with the American Heart Association Step 1 diet plus simvastatin (Sinvacor, Merck Sharp & Dohme) 40 mg/d or American Heart Association Step 1 diet alone. After the treatment period, all patients underwent endarterectomy. Fasting plasma total cholesterol, HDL cholesterol, LDL-C, and triglyceride levels were measured at baseline and before endarterectomy. Procedural methods, risk factors, and concomitant therapy did not differ between the 2 groups (Table 1 ). By the time of surgery, all patients were taking 100 mg of aspirin daily, a dose that does not affect vascular COX-2 because of rapid de novo synthesis of the enzyme in nucleated cells during the 24-hour dosing interval. 2 The study was approved by local ethics review committees. Written informed consent was obtained from all patients before each examination.
Immunohistochemistry
Samples were frozen in isopentane and cooled in liquid nitrogen. Serial sections were prepared as described previously 2 and incubated with the specific antibodies anti-CD68, anti-CD3, anti-HLA-DR, anti-␣-smooth muscle actin, and anti-CD31 (Dako Corporation); anti-COX-1, anti-COX-2, and anti-mPGES (Cayman Chemical); anti-MMP-2 and anti-MMP-9 (Calbiochem-Novabiochem); and anti-oxLDL (a gift from Dr Raffaella Muraro). In addition, 4 sections from each plaque were examined for the presence of plaque ulceration and intraplaque hemorrhage. The specimens were analyzed by an expert pathologist (intraobserver variability 6%) blinded to the patient's therapy.
Quantitative Analysis for Histology
CD3-positive T cells were counted individually and expressed as the number of cells per square millimeter of section area as determined by computer-aided planimetry (see below). Furthermore, we deter-mined the area occupied by CD68-positive and ␣-actin-positive cells planimetrically and calculated the percentage of macrophage-rich and smooth muscle cell (SMC)-rich areas. Analysis of experiments was performed with a PC-based 24-bit color image-analysis system. In brief, electronic images were digitized with a Leica CCD DC100 color video camera into a 1 kilopixel ϫ1 kilopixel image buffer of the AlphaEase 5.02 image analysis system (Alpha Innotech Corp). A color threshold mask for immunostaining was defined to detect the red color by sampling, and the same threshold was applied to all specimens. The percentage of the total area with positive color for each section was recorded.
Reverse Transcription-Polymerase Chain Reaction
COX-2 mRNA expression was evaluated by reverse transcriptionpolymerase chain reaction as described previously. 2 RNA was reverse transcribed, and first-strand cDNA was used as a template in polymerase chain reaction. cDNA aliquots were amplified with primers specific for COX-2 and GAPDH.
Western Blot
Tissue extracts (50 g of total protein/lane) were loaded with Tris-base 0.5 mol/L, 0.8% SDS, 10% glycerol, 0.3% bromophenol blue, and 5% ␤-mercaptoethanol as sample buffer and electrophoresed on 10% or 14% SDS-polyacrylamide gels. Coimmunodetection of ␤-actin was performed to ensure equal gel loading. Resolved proteins were transferred onto 0.45-m nitrocellulose membrane (Amersham Corp) in a blotting buffer that contained 25 mmol/L Tris-HCl, pH 8.3, 192 mmol/L glycine, 20% methanol, and blocked with 50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L sodium chloride, 0.3% Tween 20 (TBS-T), and 10% nonfat dried milk for at least 2 hours. The blots were washed 3 times with TBS-T and then incubated overnight with the primary antibody. After 3 washing steps (3ϫ20 minutes), the blots were incubated for 1 hour at 25°C with a horseradish peroxidase-linked anti-mouse (COX-1, COX-2, and MMPs) or anti-rabbit (mPGES) antibody (Amersham Pharmacia Biotech) at 1:1000 dilution in TBS-T containing 10% nonfat dried milk. The washing steps were repeated, and subsequently, enhanced chemiluminescence detection was performed according to the manufacturer's instructions (ECL Plus, Amersham). Intensities of experimental bands were measured by computer-assisted densitometry (Alpha Ease 5.02). 
Zymography
Zymography was performed as described previously. 2 Conditioned medium of human fibrosarcoma cell line HT1080 was used as a positive control with known gelatinolytic activity.
Oil Red O Staining for Lipid Content
Two parallel sections from each plaque specimen were incubated in 60% isopropanol for 2 minutes and then in oil red O (Carlo Erba) solution for 20 minutes and rinsed in water. One of the sections was counterstained with hematoxylin.
Sirius Red Staining for Collagen Content
Sections were performed as described by Crisby et al. 4 After dehydration, the sections were observed under polarized light after being placed on coverslips. The sections were photographed with identical exposure settings for each section.
Cell Isolation and Culture
Peripheral monocytes were purified and cultured as described previously. 2 
Results
Percentages of carotid diameter reduction did not differ between the 2 groups (Ϫ1.1Ϯ1.4% versus Ϫ0.8Ϯ1.1%).
Baseline lipid levels were similar in the 2 groups (Table 2) . At the end of the study, total cholesterol and LDL-C levels were significantly reduced in patients treated with simvastatin (Ϫ30% and Ϫ41%, respectively), whereas they did not change in patients randomized to diet alone ( Table 2) . No patient in either group developed any clinical events during the study.
Histological Analysis
Plaques of both groups had the morphology of advanced lesions, with a lipid-rich acellular core and sites of rupture (59%), superimposed thrombosis, and intraplaque hemorrhage (57%).
Cellular Composition
Macrophage and T-lymphocyte infiltration occurred coincidentally and was most prominent in the shoulder of the lesions (Figure 1 ). Plaque area occupied by macrophages and T cells was significantly smaller (PϽ0.0001) in plaques from the simvastatin group than in plaques from the control group (Table 1 ). In contrast, staining for ␣-actin was higher in simvastatin-treated plaques than in control plaques (Table 1) .
Macrophage Activation Status
Control plaques were always characterized by strong expression of HLA-DR antigens, which contrasted with the low expression of HLA-DR in the simvastatin-treated plaques (Figure 1 ). HLA-DR expression was most abundant on macrophages and lymphocytes, but HLA-DRϩ SMCs also occurred, although these were limited to sites adjacent to inflammatory infiltrates.
COX-2 Expression in Plaques Is Reduced by Simvastatin
After treatment, COX-2 was more abundant in control lesions than in plaques from simvastatin-treated subjects (23.2Ϯ5.2% versus 6.1Ϯ2.2%, nϭ35; PϽ0.0001; Figure 2 ). COX-2 accumulated in the activated macrophages at the shoulder region in control subjects, whereas it was localized primarily in SMCs in simvastatin-treated patients. Finally, Western blot and reverse transcription-polymerase chain reaction analyses (Figure 3 ) confirmed markedly lower COX-2 expression in simvastatin-treated plaques (6158Ϯ152 versus 1236Ϯ321 densitometric units [DU] for protein ex- pression, nϭ35; PϽ0.0001). In contrast, no significant effects were observed with respect to COX-1 expression ( Figure 2 ).
mPGES Expression in Plaques Is Reduced by Simvastatin
Immunohistochemistry revealed strong mPGES immunoreactivity in all of the control plaques but only weak staining in the simvastatin-treated plaques (19.6Ϯ3.2% versus 3.7Ϯ1.3%, nϭ35; PϽ0.0001; Figure 2 ). In the control group, mPGES localized in the plaque shoulder, an area characterized as macrophage rich. Only weak mPGES expression was observed by Western blot in simvastatin-treated plaques (Figure 3) . In contrast, a 5-fold higher signal was demonstrated in control plaques (946Ϯ265 versus 5163Ϯ194 DU, nϭ35; PϽ0.0001).
Effect of Simvastatin on MMP Expression in Plaques
MMP staining was significantly less abundant in lesions from simvastatin-treated patients than in controls (Figure 2 ). Levels of MMP-2 and MMP-9 in control plaques (24.6Ϯ4.7% and 26.2Ϯ5.6%, respectively; nϭ35) significantly exceeded (PϽ0.0001) those in simvastatin-treated plaques (6.4Ϯ1.9% and 7.2Ϯ2.5%, respectively; Table 1 ). Immunoreactivity localized in the plaque shoulder, corresponding to areas of intense macrophage infiltration.
Effect of Simvastatin on MMP Activity in Plaques
The higher (PϽ0.0001) MMP-2 and MMP-9 immunoreactivity documented by Western blot in control plaques (6231Ϯ284 versus 1894Ϯ187 and 6745Ϯ421 versus 2745Ϯ347 DU, respectively; nϭ35; Figure 4A ) does not necessarily correspond to enhanced enzymatic activity, because all MMPs require activation before they can digest their substrate. 6 Thus, we used zymography to demonstrate that control plaques contained activated MMPs ( Figure 4B ). In contrast, only weak positivity for activated MMPs was observed in simvastatin-treated plaques ( Figure 4B ). Thus, the amount of inactive and active MMP-2 (5247Ϯ285 versus 1145Ϯ275 and 2874Ϯ302 versus 598Ϯ124 DU, respectively; nϭ35) and MMP-9 (6136Ϯ368 versus 1321Ϯ354 and 2645Ϯ641 versus 876Ϯ221 DU, respectively) was significantly higher (PϽ0.0001) in the control plaques.
Effect of Simvastatin on Plaque Extracellular Components
Sirius red polarization showed increased collagen content in the sections of simvastatin-treated patients compared with control patients (15.2Ϯ3.4% versus 8.1Ϯ3.8%, nϭ35; PϽ0.0001). In contrast, the plaque content of lipid ( Figure  5A ) and oxLDL ( Figure 5B ) was significantly reduced after simvastatin therapy (27.2Ϯ11.5% versus 6.9Ϯ4.1% and 25.3Ϯ5.8% versus 10.7Ϯ2.8%, respectively; nϭ35; PϽ0.0001).
Lipid-Lowering-Dependent Effect of Simvastatin on PGE 2 -Induced MMP Biosynthesis
To determine whether simvastatin regulates MMPs through COX-2/mPGES inhibition, we examined the effect of simvastatin on MMP production ( Figure 6 ). Lipopolysaccharide caused an enhancement (PϽ0.0001, nϭ35) in COX-2 (1021Ϯ113 versus 6742Ϯ147 DU), mPGES (1016Ϯ91 versus 5936Ϯ164 DU), MMP-2 (1654Ϯ163 versus 6724Ϯ202 DU), and MMP-9 (1321Ϯ174 versus 6925Ϯ231 DU) levels over that detected in control monocytes. Enzyme induction by lipopolysaccharide was significantly (PϽ0.0001) inhibited by simvastatin (1136Ϯ134, 1201Ϯ124, 1721Ϯ132, and 1432Ϯ156 DU, respectively); however, the inhibition was reversed by the addition of mevalonate. Similar results were also observed when interleukin-1␤ was used as a stimulus. Thus, MMP inhibition by simvastatin appears secondary to the reduction of cholesterol biosynthesis and the subsequent downregulation of COX-2/mPGES-dependent PGE 2 production.
Discussion
We 2 have previously reported that COX-2 and mPGES contribute to the clinical instability of atherosclerotic plaques by promoting plaque rupture induced by MMPs, key enzymes in the final step of this process. Now, in the present report, we provide evidence for the critical involvement of COX-2/ mPGES in the process of plaque stabilization induced by simvastatin therapy. The present findings are the first, to the best of our knowledge, to (1) demonstrate by randomized study the anti-inflammatory effect of statins in human carotid atherosclerotic plaques, (2) show a direct inhibitory effect of simvastatin on COX-2/mPGES in human atherosclerotic lesion, and (3) relate the inhibition of COX-2/mPGES to the reduction of MMP activity observed after statin therapy. Concomitantly higher expression of COX-2/mPGES, MMP-2, and MMP-9 was found in specimens obtained from the culprit carotid lesions of patients randomized to diet alone compared with specimens obtained from patients randomized to simvastatin. In particular, all plaques obtained from simvastatin-treated patients exhibited only weak positivity, whereas only 3 (8.5%) of 35 plaques randomized to diet alone demonstrated intensity of enzyme expression comparable to that observed in simvastatin-treated plaques. Notably, the positive impact of statin-dependent MMP suppression was confirmed by the parallel increment in plaque collagen content after simvastatin therapy.
In the present study, macrophages were more abundant in control plaques, always outnumbered the lymphocytes, and represented the major source of COX-2/mPGES and MMPs. Furthermore, the site of inflammatory infiltration in control plaques was always characterized by strong expression of HLA-DR antigens on inflammatory cells, which contrasted with the low expression of HLA-DR elsewhere in the simvastatin-treated plaques. These data suggest the ability of simvastatin to reduce the inflammatory reaction in symptomatic plaques. In fact, in agreement with the difference in COX-2/mPGES and MMP staining pattern, the histological milieu of the lesions appears different with regard to cellularity, presence of foam cells, cholesterol clefts, and collagen content but not in the degree of vessel stenosis, which suggests that lesions treated with simvastatin or diet alone are different only with regard to inflammatory burden and that differences in plaque behavior stem from differences between simvastatin and diet alone in the ability to influence the expression of 1 or more proteins capable of disrupting plaque stability.
Previous studies have reported the ability of statins to reduce atherosclerotic lesion evolution toward rupture. 4 However, these studies did not provide any evidence about the involvement of COX-2/mPGES in the pathophysiology of simvastatin-dependent plaque stabilization. COX-2 is an intermediate enzyme in the metabolic pathway of arachidonic acid, and the COX bioproduct PGH 2 is further metabolized by other isomerases to various prostanoids. Thus, the relative abundance of a specific prostanoid rather than another is the result of the expression and activity of its specific isomerase, and the concomitant expression of functionally coupled COX-2/mPGES is necessary for the biosynthesis of PGE 2dependent MMPs in the setting of atherosclerotic plaque.
Interestingly, because macrophages of the shoulder region contain most of the COX-2/mPGES protein within the lesion, they emerge as the principal cellular target of simvastatin in the context of plaque stabilization. This finding may have functional importance and may contribute to explain the controversial experimental 7, 8 and clinical 9 findings associated with selective COX-2 inhibition, because different cell types can regulate the production of different eicosanoids. Endothelium predominantly releases PGI 2 , an inhibitor of platelet activation and cholesterol accumulation, and Belton et al 10 reported that COX-2 is responsible for the increase in PGI 2 seen in patients with atherosclerosis. In contrast, macrophages, not present in normal arterial tissue, produce an array of prostanoids, including PGE 2 , considered one of the most atherogenic eicosanoids.
Prostanoids have potent actions on SMCs, regulating contractility, cholesterol metabolism, and proliferation. 11 Reduced expression of COX might thus contribute to the decrease of lipid accumulation in lesional SMCs (and macrophages), reducing formation of SMC-and macrophage-derived foam cells within atheroma. On the other hand, antiproliferative and antimigratory 12 actions of COX products on SMCs suggest potential contributions of the inhibition of this enzyme to the evolution of a lesion toward an SMC-enriched and macrophage-depleted, and thus more stable, plaque. Furthermore, COX-2 can modulate angiogenesis by synthesis of angiogenic factors and neovessel formation. Consequently, COX-2 inhibition within the lesion contributes to the reduction of new blood vessel formation, thus inhibiting plaque expansion. 13 More importantly, PGE 2 , a predominant eicosanoid of macrophages, induces in human atherosclerotic plaques the expression of MMP-2 and MMP-9, enzymes considered crucial in the degradation of plaque stability. 2 Our description of a strong reduction of these MMPs in plaque treated with simvastatin and found to be macrophagedepleted and COX-2/mPGES-negative suggests that such arachidonate-dependent inhibition of MMPs by simvastatin may operate in vivo. Interestingly, these data obtained in patients with only modest increments in LDL-C are in accord with the results of the recent Heart Protection Study 3 and provide further support against the existence of an LDL-C threshold below which reductions would not reduce risk.
The present results are partially in agreement with Crisby et al 4 because they demonstrate reduced MMP-2 activity in statin-treated plaques. However, in the present study, simvastatin also significantly reduced MMP-9 activity and increased the plaque content of SMCs, whereas in the study by Crisby et al, 4 pravastatin failed to obtain these results. Several hypotheses could be raised to explain these conflicting data. First, the study by Crisby et al, 4 despite being well designed, was a nonrandomized study, and thus, hidden biases could explain the different results. Alternatively, the different statin used, the stronger lipid-lowering effect, or the longer period of treatment might all contribute to explain the observed differences.
The present report is also in accord with recent in vitro evidences 14 demonstrating that atorvastatin may reduce inflammation by decreasing COX-2 expression in SMCs, although it differs from the report of Degraeve et al, 15 which showed that mevastatin and lovastatin may upregulate COX-2 expression in SMCs in vitro. These contradictory data suggest that different statins may exert diverse effects on the complex signal transduction pathways involved in COX-2 regulation.
In the present study, the hypothesis that plaque COX-2/ mPGES suppression by simvastatin was largely dependent on the reduction in plaque cholesterol was supported by the in vitro experiments with mevalonate and by the observation that reduction of COX-2/mPGES in plaque was associated with comparable reduction in oxLDL content. However, further studies directly comparing simvastatin with other lipid-lowering strategies are necessary to definitively answer this question.
In conclusion, the present study addresses the missing link between statin therapy and MMP inhibition that leads in turn to plaque stabilization, by demonstrating the inhibition of the functionally coupled COX-2/mPGES in human atherosclerotic lesions after simvastatin therapy and providing evidence that downregulation of COX-2/mPGES in activated macrophages by simvastatin is associated with plaque stabilization, possibly by suppression of MMP-induced matrix degradation, which promotes plaque rupture. These findings are potentially important from a fundamental standpoint because they indicate a crucial role for inducible COX/PGES in the stabilization of atherosclerotic lesions observed with statins. From a practical standpoint, these findings provide further support for the possibility that statins might provide a novel form of therapy for plaque stabilization in patients with atherosclerotic disease.
